Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mollnes, T. E.
Right arrow Articles by Rekvig, O. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mollnes, T. E.
Right arrow Articles by Rekvig, O. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 1999; 38: 933-940
© 1999 British Society for Rheumatology

Complement activation in patients with systemic lupus erythematosus without nephritis

T. E. Mollnes, H.-J. Haga1, J. G. Brun2, E. W. Nielsen3, A. Sjöholm4, G. Sturfeldt5, U. Mårtensson4, K. Bergh6 and O. P. Rekvig7

Department of Immunology and Transfusion Medicine and
3 Department of Anaesthesiology, Nordland Central Hospital, Bodø,
1 Department of Rheumatology and
7 Institute of Medical Biology, University of Tromsø,
2 Department of Rheumatology, Haukeland University Hospital, Bergen,
6 Department of Microbiology, University of Trondheim, Norway and
4 Department of Medical Microbiology and
5 Department of Rheumatology, University of Lund, Sweden

Correspondence to: T. E. Mollnes, Department of Immunology and Transfusion Medicine, Nordland Central Hospital, N-8092 Bodø, Norway.

Objective. To study the association between disease activity and complement activation prospectively in patients with systemic lupus erythematosus (SLE).

Patients and methods. Twenty-one SLE patients were examined monthly for 1 yr. Disease activity, autoantibodies, conventional complement tests and the following complement activation products were investigated: C1rs–C1inh complexes, C4bc, Bb, C3a, C3bc, C5a and the terminal SC5b–9 complement complex (TCC).

Results. Modest variation in disease activity was noted. None of the patients had nephritis. Flare was observed at 27 visits. Four patients had anti-C1q antibodies in conjunction with modestly low C1q concentrations. The complement parameters were rather constant during the observation period. Slightly to moderately decreased C4 (0.05–0.10 g/l) was found in 10 patients and severely decreased C4 (<0.05 g/l) in seven patients. Decreased C4 was not associated with increased complement activation. Complement activation products were either normal or slightly elevated. TCC was the only activation product correlating significantly with score for disease activity at flare. None of the variables tested predicted flares.

Conclusion. Complement tests are of limited importance in routine examination of SLE without nephritis, although TCC is suggested to be one of the most sensitive markers for disease activity.

KEY WORDS: Systemic lupus erythematosus, Complement, Terminal complement complex.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
G. Sturfelt and L. Truedsson
Complement and its breakdown products in SLE
Rheumatology, October 1, 2005; 44(10): 1227 - 1232.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.